Search
Pacira Biosciences Inc
PCRXAdd to Watchlist
24.670USD
+0.190+0.78%
Close 09-17 16:00（ET）
982.42MMarket Cap
195.93P/E TTM
Pacira Biosciences Inc (PCRX) Stock Price Target & Forecast
Analyst Rating
Based on 6 analysts giving stock ratings to Pacira Biosciences Inc in the past month.
Buy
1 Strong Buy
2 Buy
2 Hold
1 Sell
0 Strong Sell
Target Price
28.857USD+19.84%
PCRX Analyst Recommendation Trends
In the current month, PCRX has received 2 Buy Ratings, 2 Hold Ratings, and 1 Sell Ratings. PCRX average Analyst price target in the last month is 28.857.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
1
1
1
1
1
1
1
1
2
2
3
3
3
3
3
3
2
2
2
2
2
2
2
2
0
0
0
0
0
0
0
0
1
1
1
1
1
1
1
1
6
6
7
7
7
7
7
7
PCRX Analyst Rating for Peer Comparison
Updated: Sep 17, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Amgen Inc
AMGN
4
12
18
2
1
37
Biogen Inc
BIIB
7
17
12
1
0
37
Eli Lilly and Co
LLY
10
17
6
1
0
34
AbbVie Inc
ABBV
8
19
6
0
0
33
Pfizer Inc
PFE
5
6
19
1
1
32
Merck & Co Inc
MRK
8
14
10
0
0
32
Gilead Sciences Inc
GILD
7
18
6
0
0
31
Vertex Pharmaceuticals Inc
VRTX
9
16
5
0
1
31
Regeneron Pharmaceuticals Inc
REGN
6
14
10
0
0
30
Alnylam Pharmaceuticals Inc
ALNY
5
18
7
0
0
30
Financial Forecasting
Based on analysts' estimates, PCRX EPS is projected to reach 0.724 in FY2026Q3, following reported EPS of 0.118 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
0.90
0.56
0.65
0.72
0.83
Actual
0.04
0.07
0.12
--
--
Surprise
-95.74%
-87.21%
-81.79%
--
--
FAQs
What is Pacira Biosciences Inc's expected revenue for the next quarter?
Pacira Biosciences Inc's expected revenue is 182.11M.
What is Pacira Biosciences Inc's price target?
Analysts forecast that Pacira Biosciences Inc's price target is USD 28.86, with the highest forecast at USD 38.00 and the lowest forecast at USD 23.00.
How have Pacira Biosciences IncPCRX's recent earnings per share performed?
The market expectation was USD 0.12, while Pacira Biosciences IncPCRX's earnings per share (EPS) for the previous quarter was USD 0.07. EPS for the next quarter is expected at USD 0.72.
What is the analyst rating for Pacira Biosciences Inc?
Based on the ratings of Pacira Biosciences Inc's stock from 6 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.